Interleukin‐1 blockade treatment decreasing cardiovascular risk

• Published in: Clinical cardiology (Mahwah, N.J.) Vol. 42; no. 10; pp. 942 - 951
• Main Authors: Zheng, Zi‐Heng, Zeng, Xun, Nie, Xiao‐Ying, Cheng, Yun‐Jiu, Liu, Jun, Lin, Xiao‐Xiong, Yao, Hao, Ji, Cheng‐Cheng, Chen, Xu‐Miao, Jun, Fan, Wu, Su‐Hua
• Format: Journal Article
• Language: English
• Published: New York Wiley Periodicals, Inc 01.10.2019
• Subjects: anakinra; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - therapeutic use; canakinumab; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; cardiovascular events; Cause of Death; Clinical Investigations; Global Health; Humans; Incidence; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Interleukin-1 - antagonists & inhibitors; Interleukin-1 - blood; Interleukin‐1 blockade; meta‐analysis; Recombinant Fusion Proteins - therapeutic use; Risk Factors; cardiovascular events; meta-analysis; anakinra; canakinumab; Interleukin-1 blockade

Background Interleukin‐1 (IL‐1) played a role in the occurrence and development of atherosclerosis and cardiovascular events. However, the association between IL‐1 blockage treatment and reducing of cardiovascular risk remains poorly defined. Hypothesis IL‐1 blockage treatment reduce the risk and in...